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Background: Positivity of plasma Epstein–Barr virus (EBV)-DNA or serum virus capsid antigen-speciﬁc IgA (VCA-
IgA) is a biomarker for the prognosis of nasopharyngeal carcinoma (NPC). The objective of this study was to de-
termine the value of positivity for plasma EBV-DNA and/or VCA-IgA in predicting the survival of patients with
NPC.
Methods: Plasma EBV-DNA and serum VCA-IgA in 506 NPC patients in this retrospective study were detected by
quantitative real time polymerase chain reaction and enzyme-linked immunoabsorbent assay, respectively. The
value of positivity for EBV-DNA and/or VCA-IgA in predicting the survival of patients with NPC was analyzed.
Results: Patients with positivity for both EBV-DNA and VCA-IgA had signiﬁcantly shorter periods of relapse free
survival (RFS) and overall survival (OS) than those with positive single measure or negative for both measures,
and patients with positive single measure had signiﬁcantly shorter periods of RFS and OS than those with nega-
tive for both. Multivariate analysis indicated that the positivity for EBV-DNA and/or VCA-IgAwere signiﬁcant risk
factors for shorter periods of RFS and OS.
Conclusion: These data indicated that positivity for both EBV-DNA and VCA-IgA was a better biomarker for the
prognosis of patients with NPC. Our ﬁndings may provide new references for clinical practice.© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Nasopharyngeal carcinoma (NPC) is a unique type of cancers in the
head and neck because of its epidemiology, histopathology, clinical
characteristics, therapeutic strategies, and treatment outcomes. Cur-
rently, the incidence of NPC in the Southern China and Asia is especially
high, nearly 30 per 100,000 [1]. While radiotherapy is considered as the
primary strategy for treatment of NPC patientswithout distantmetasta-
sis, [2] chemoradiotherapy is a better therapeutic modality for patients
with advanced disease [3]. Although these therapeutic strategies have
signiﬁcantly improved the survival rate and life quality of patients
with NPC, the 5-year survival probability is still low in NPC patients
due to the disease recurrence and distant metastasis [4]. Hence,86 20 81332833.
1162@qq.com (X.-P. Li).
pen access article under the CC BY-Ndiscovery of risk factors for the recurrence and metastasis will be of
great signiﬁcance in the prognosis and management of NPC patients.
It is well known that Epstein–Barr virus (EBV) infection is associated
with NPC. Indeed, the EBV DNA can be detected in NPC cells [5–8]. Pre-
vious studies have shown that plasma EBV-DNA [9–15] and serum EBV
capsid antigen-speciﬁc IgA (VCA-IgA) [16–21] are detected in patients
with NPC and have been used as biomarkers for screening, diagnosis,
monitoring, and prognosis of NPC. Indeed, the levels of plasma EBV-
DNA loads in newly diagnosed NPC patients are signiﬁcantly correlated
with tumor volume [22,23], tumor clearance [24,25], poor responses to
chemoradiation [26], and tumor recurrence [27–29]. Similarly, seropos-
itive VCA-IgA is associated with increased risk for NPC [30,31] and NPC
patients with higher levels of VCA-IgA have a worse prognosis [18–21].
It has been thought that plasma EBV-DNAcan bederived from apoptotic
tumor fragments and VCA-IgA reﬂects mucosal immune responses to
EBV replication. They are different biological events, associated with
the development of NPC. However, some patients are only positive for
EBV-DNA or VCA-IgA and the value of plasma EBV-DNA or VCA-IgA
for the prognosis is inconsistent [9,20,32–35]. Currently, there is noC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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VCA-IgA in the prognosis of NPC. Indeed, it is unclearwhether combined
plasma EBV-DNA and serum VCA-IgA can be a better marker for the
prognosis of NPC patients. Given that identiﬁcation of risk for disease re-
currence and poor survival in NPC patients is crucial for early interven-
tion, addressing these questions will beneﬁt patients with NPC. It is
urgent to determine the prognostic values of positive plasma EBV-
DNA and/or seropositive VCA-IgA in NPC patients.
The objective of this study was to determine whether positivity for
plasma EBV-DNA and/or VCA-IgA could be a better biomarker for
predicting the poor survival of patients with NPC. A total of 506 patients
with NPC were selected for this retrospective study. The presence of
plasma EBV-DNA and serum VCA-IgA in these patients was determined
before treatment. Subsequently, these patients were stratiﬁed and the
association of positivity for both or single measure with the disease re-
lapse, mortality, relapse free survival (RFS) and overall survival (OS) of
NPC patients was analyzed. We found that the positivity for both mea-
sureswas associatedwith signiﬁcantly higher rates ofmortality and dis-
ease relapse, as well as shorter periods of RFS and OS than that in those
with positivity for singlemeasure or negativity for bothmeasures in this
population. We discussed the implications of our ﬁndings.
2. Materials and methods
2.1. Patients and clinical specimens
A total of 506 patients with biopsy-proven, newly diagnosed NPC
were selected fromDepartment of Otolaryngology—Head andNeck Sur-
gery of Nanfang Hospital in Southern Medical University from January
2006 to April 2013. Individual patients with NPC were diagnosed,
based on the pathological examination of biopsied tissues. The patho-
genic stages of individual patients were according to the 2002
American Joint Committee on Cancer TNM staging system. Individual
patients with another type of tumor were excluded.
Venous blood samples were collected from individual patients be-
fore treatment. Their plasma and serum samples were prepared. The
tests of plasma EBV-DNA and VCA-IgA were performed by the Depart-
ment of Laboratory of Nanfang Hospital. This study was approved by
the Institutional Review Board of our hospital, and written informed
consent about analysis of their clinical parameters was obtained from
individual patients before treatment.
2.2. Clinical management
All patients received conventional two-dimensional radiotherapy
uniformly administered to the primary tumor and neck region with a
total dose of 66 to 70 Gy over a 6–8-week period. There were 410
(81.03%) patients with advanced disease (T3–T4 or N2–N3) who also
received induction chemotherapy prior to radiation or adjuvant chemo-
therapy after radiation.
After the last chemoradiotherapy, all patients were examined at 3, 6,
and 12 months in the ﬁrst year, every 6 months during the second and
third years, and yearly thereafter. The recurrence of NPC was evaluated
by clinical physical examination, magnetic resonance imaging (MRI)
and/or computed tomography (CT) scans from the skull base to the
whole neck, chest radiography, whole-body bone scan, abdominal so-
nography, ﬁber nasopharyngoscopy and biopsied pathologic veriﬁca-
tion if necessary. PET-CT examination was used to ensure distant
metastasis.
2.3. Quantiﬁcation of plasma EBV-DNA
The total plasma DNA was extracted and the contents of plasma
EBV-DNA were quantiﬁed by quantitative real time polymerase chain
reaction (qRT-PCR) using an EBV RT-PCR kit (Liferiver, Shanghai,China), according to the manufacturers' instruction. The cut-off value
for a positive plasma EBV DNA load is N0 copy/ml.
2.4. Serologic analysis of VCA-IgA
The concentrations of serum VCA-IgA were determined by enzyme-
linked immunoabsorbent assay (ELISA) using a speciﬁc kit (Beier,
Beijing, China), according to the manufacturers' instruction. The cut-
off value for positive EBV VCA-IgA is optical density (OD) of N1.
2.5. Statistical analyses
Data shown are the case numbers and the median and range. Pa-
tients were stratiﬁed, according to individual measures and the relapse
and mortality rates of each group of patients were analyzed by the chi-
square test. The RFS was calculated from the ﬁrst day of induction che-
motherapy to the date of either disease recurrence or the last follow-up
visit. The OSwas calculated from the ﬁrst day of induction chemothera-
py to the date of either death or the last follow-up visit. The periods of
RFS and OS among the different groups of patients were evaluated by
Kaplan–Meier method and analyzed by the log-rank test. The potential
risk of age, gender, tumor classiﬁcation, lymph node status, metastasis
status and status of plasma EBV-DNA and VCA-IgA for the poor survival
of NPC patients was analyzed by hazard ratio (HR), 95% conﬁdence in-
terval (CI) and theWald test usingmultivariate Cox proportional hazard
model. All statistical analyses were performed by SPSS (version 19.0 for
window; Statistical Product and Service Solutions; IBM). A two-tailed
P value of b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Patients' characteristics
To determine the potential importance of plasma EBV-DNA and
serum VCA-IgA positivity in the prognosis of NPC, 506 patients with
newly diagnosed NPC were selected. The demographic and clinical
characteristics are shown in Table 1. There were 69.56% of patients
with positive plasma EBV-DNA and 45.85% of patients with positive
serum VCA-IgA in this population. Stratiﬁcation of patients, according
to the positivity of EBV-DNA and VCA-IgA indicated that therewas a sig-
niﬁcant difference in the percentages of NPC patients with positivity for
EBV-DNA alone, for VCA-IgA alone, for both EBV-DNA and VCA-IgA and
negativity for both measures (P = 0.008) (Table 2). A total of 175
(34.58%) patients were positive for both plasma EBV-DNA and serum
VCA-IgA, 177 (34.98%) patients with positive plasma EBV-DNA alone,
57 (11.27%) patients with positive serum VCA-IgA alone and 97
(19.17%) patients with negative plasma EBV-DNA and serum VCA-IgA.
There was no signiﬁcant difference in the distribution of age, gender,
and pathologic classiﬁcation among these four groups of patients. How-
ever, there was a signiﬁcant difference in the distribution of tumor clas-
siﬁcation, lymph node status, metastasis status and overall stage among
these four groups of patients. During the median observation of 37
(range 5 to 75) months, there were 116 (22.92%) patients with NPC re-
currence and 96 (18.97%) patients died. During the same period, there
were 23 patients with NPC relapse in nasopharynx and 8 in neck,
while 68 patients developed distant metastasis, 10 with nasopharynx
relapse and distant metastasis, and 7 with neck relapse and distant
metastasis.
3.2. Survival analysis
Stratiﬁcation analyses indicated that there was a signiﬁcant differ-
ence in the rates of NPC relapse and mortality among these four groups
of patients (P b 0.001 for both) (Fig. 1A,C). As a result, therewas a signif-
icant difference in the periods of RFS andOS among these four groups of
patients (P b 0.001 for both) (Fig. 1B,D). Further analyses revealed that
Table 1
The demographic and clinical characteristics of NPC patients.
Characteristic All EBV-DNA+/VCA-IgA+ EBV-DNA+/VCA-IgA− EBV-DNA−/VCA-IgA+ EBV-DNA−/VCA-IgA− P values
Case no. 506 175 (34.58) 177 (34.98) 57 (11.27) 97 (19.17) Pa b 0.001
Age (yrs) Pb = 0.478
Median 44 47 45 48 46
Range 17–80 17–80 18–77 17–75 19–70
Gender Pa = 0.153
Male 380 (75.10) 142 (81.14) 128 (72.32) 41 (71.93) 69 (71.13)
Female 126 (24.90) 33 (18.86) 49 (27.68) 16 (28.07) 28 (28.87)
WHO pathologic classiﬁcation Pb = 0.362
Type I 9 (1.78) 2 (1.14) 1 (0.56) 2 (3.51) 4 (4.12)
Type II 22 (4.35) 9 (5.14) 8 (4.52) 2 (3.51) 3 (3.09)
Type III 475 (93.87) 164 (93.72) 168 (94.92) 53 (92.98) 90 (92.79)
Tumor classiﬁcation Pb b 0.001
T1 84 (16.60) 25 (14.29) 20 (11.30) 11 (19.30) 28 (28.87)
T2 110 (21.74) 31 (17.71) 37 (20.90) 17 (29.82) 25 (25.77)
T3 153 (30.24) 63 (36.00) 53 (29.95) 16 (28.07) 21 (21.65)
T4 159 (31.42) 56 (32.00) 67 (37.85) 13 (22.81) 23 (23.71)
Lymph node status Pb b 0.001
N0 55 (10.87) 10 (5.71) 13 (7.35) 14 (24.56) 18 (18.56)
N1 156 (30.83) 33 (18.86) 61 (34.46) 18 (31.58) 44 (45.36)
N2 206 (40.71) 86 (49.14) 73 (41.24) 21 (36.84) 26 (26.80)
N3 89 (17.59) 46 (26.29) 30 (16.95) 4 (7.02) 9 (9.28)
Metastasis status Pa = 0.004
M0 478 (94.47) 162 (92.57) 162 (91.53) 57 (100) 97 (100)
M1 28 (5.53) 13 (7.43) 15 (8.47) 0 (0) 0 (0)
Overall stage Pb b 0.001
I 14 (2.77) 1 (0.57) 2 (1.13) 3 (5.26) 8 (8.25)
II 82 (16.21) 17 (9.71) 20 (11.30) 18 (31.58) 27 (27.84)
III 177 (34.98) 63 (36.00) 62 (35.03) 20 (35.09) 32 (32.99)
IV 233 (46.04) 94 (53.72) 93 (52.54) 16 (28.07) 30 (30.92)
Data shown are the real case numbers (%), unless speciﬁed. Pa values were determined using the chi-square test; Pb values were determined using the k independent samples test.
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and VCA-IgA were signiﬁcantly shorter than that of patients with posi-
tivity for EBV-DNA alone, with positivity for VCA-IgA alone and those
with negativity for both EBV-DNA and VCA-IgA (Supplementary
Table 1). The periods of RFS and OS in patients with positive plasma
EBV-DNA alone were signiﬁcantly shorter than that of patients with
negativity for both (P= 0.006 for both). However, there was no signif-
icant difference in the periods of RFS and OS between the patients with
positive EBV-DNA alone andwith seropositive VCA-IgA alone. Similarly,
therewas no signiﬁcant difference in the periods of RFS andOS between
the patients with seropositive VCA-IgA alone and those with negativity
for both EBV-DNA and VCA-IgA. Accordingly, the risk for NPC relapse
and mortality in patients with positivity for both EBV-DNA and VCA-
IgA was higher than that of those with positivity for EBV-DNA alone,
which was also higher than that of patients with positivity for VCA-
IgA alone and those with negativity for both measures.
Given small sample size and no signiﬁcant difference in the periods
of RFS and OS between the patients with single positivity of either EBV-
DNA or VCA-IgA, we further combined these two groups of patients to
analyze the relapse and mortality rates and the periods of RFS and OS
among these three groups of patients. First, there was a signiﬁcant dif-
ference in the relapse and mortality rates among these three groups of
patients (P b 0.001 for both) (Fig. 2A,C). Similarly, there was a signiﬁ-
cant difference in the periods of RFS and OS among these three groups
of patients (P b 0.001 for both) (Fig. 2B,D). Further analyses revealed
that the periods of RFS and OS in the patients with positivity for bothTable 2
The positivity of plasma EBV-DNA and serum VCA-IgA.
VCA-IgA
Positive Negative
EBV-DNA Positive 175 (34.58%) 177 (34.98%)
Negative 57 (11.27%) 97 (19.17%)EBV-DNA and VCA-IgA were signiﬁcantly shorter than that of patients
with single positivity of EBV-DNA or VCA-IgA (P = 0.003 for RFS;
P = 0.004 for OS) (Supplementary Table 2) and those with negativity
for both (P b 0.001 for both). Interestingly, the periods of RFS and OS
in the patients with single positivity of EBV-DNA or VCA-IgA were sig-
niﬁcantly shorter than that of those with negativity for both measures
(P = 0.011 for RFS; P = 0.010 for OS). These data further indicated
that the risk for relapse and mortality in NPC patients with positivity
for both EBV-DNA and VCA-IgA was higher than that of patients with
single positive EBV-DNA or VCA-IgA, which also was higher than that
of those with negativity for both measures.3.3. Cox multivariate analysis
Next, we performed themultivariate analysis using themultivariate
Cox proportional hazard model. The lymph node metastasis was a sig-
niﬁcant risk factor for the shorter RFS periods in NPC patients (HR:
1.555; 95% CI: 1.248–1.937; P b 0.001) (Table 3). Similarly, the older
age (HR: 1.976; 95% CI: 1.268–3.079; P= 0.003), higher tumor classiﬁ-
cation (HR: 1.378; 95% CI: 1.118–1.698; P= 0.003), lymphnodemetas-
tasis (HR: 1.639; 95% CI: 1.261–2.131; P b 0.001) and metastasis (HR:
4.842; 95% CI: 2.721–8.618; P b 0.001) were signiﬁcant risk factors for
shorter periods of OS in NPC patients. The positivity for EBV-DNA and/
or VCA-IgA were identiﬁed as signiﬁcant risk factors for shorter periods
of RFS (P= 0.001) and OS (P= 0.002). In comparison with that in the
patients with negativity for both EBV-DNA and VCA-IgA with a desig-
nated HR of 1, the positivity for both EBV-DNA and VCA-IgA (HR:
3.644; 95% CI: 1.717–7.732; P = 0.001), single positive EBV-DNA or
VCA-IgA (HR: 2.400; 95% CI: 1.131–5.096; P = 0.023), were signiﬁ-
cant risk factors for the shorter RFS periods. Furthermore, the posi-
tivity for both EBV-DNA and VCA-IgA (HR: 3.972; 95% CI: 1.554–
10.153; P= 0.004), but not positive single EBV-DNA or VCA-IgA (HR:
2.226; 95% CI: 0.863–5.739; P = 0.098), was a signiﬁcant risk factor
for the shorter OS periods in NPC patients.
Fig. 1. Stratiﬁcation analyses of the survival of NPC patients. All of theNPC patients were stratiﬁed, according to the detection of EBV-DNA and VCA-IgA and their NPC relapse andmortality
were calculated. Subsequently, the periods of RFS and OS of individual groups of patients were estimated by the Kaplan–Meier method and analyzed by the Log rank test. (A) The per-
centages of relapse. (B) The percentages of RFS in the different groups of NPC patients throughout the observation period. (C) The percentages of mortality. (D) The percentages of OS
in the different groups of patients throughout the observation period.
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Previous studies have shown that positive plasma EBV-DNA or
serum VCA-IgA is prognostic factor for the relapse and survival of NPC
patients [12–15,18–21,27]. However, these markers do not always ap-
pear simultaneously in NPC patients [9,20,32–34]. In this retrospective
study, we compared the risks of positivity for EBV-DNA and/or VCA-
IgA in predicting the relapse of NPC and the survival of 506NPCpatients.
We found 69.56% of patients with positive plasma EBV-DNA and 45.85%
of patientswith positive serumVCA-IgA in this population. According to
the positive detection of EBV-DNA and VCA-IgA, there were four groups
of patients with positivity for both EBV-DNA and VCA-IgA, EBV-DNA
alone, VCA-IgA alone, and negative for both measures. The percentages
of patients with both EBV-DNA and VCA-IgA or EBV-DNA alone were
signiﬁcantly higher than that of those with positive VCA-IgA alone or
negative both measures. These data suggest that majority of NPC pa-
tients had EBV infection and some patients developed IgA responses
to VCA in this population. These data also support the notion that EBV
infection is associated with the development of NPC [5–8].
EBV-DNA and VCA-IgA have been routinely tested in NPC patients
and positive plasma EBV-DNA or serum VCA-IgA is a prognostic factor
for the relapse and survival of NPC patients. In this study, the positivity
rates in detection of EBV-DNA in NPC patients were signiﬁcantly higher
than that of VCA-IgA, consistent with previous reports [32–34]. Howev-
er, therewere still more than 30%of NPC patientswhowere negative for
EBV-DNA. If combinedwith VCA-IgA, the detection sensitivity is 80.83%,
better than EBV-DNA alone. The combination of EBV-DNA and VCA-IgA
may be more suitable to diagnose NPC. Baizig [20] also reported that
there was no signiﬁcant correlation between the levels of plasma EBV-
DNA and serum VCA-IgA in NPC cases. Twu [35] reported that EBV-
DNA is superior to VCA-IgA in prognostic prediction of NPC. However,we found that patients with positivity for both measures had a worse
prognosis than those with positivity for EBV-DNA alone (Fig. 1), and
VCA-IgA can also predict the prognostic of NPC in our study (Supple-
mentary Fig. 1). Therefore, positivity for both EBV-DNA and VCA-IgA is
a better marker for the prognosis of NPC patients.
Physicians are commonly confused with biomarkers for the progno-
sis of NPC patients because of the inconsistence of positivity for EBV-
DNA and VCA-IgA. We compared the periods of RFS and OS among
these 506 patients. We found that patients with positivity of both mea-
sures had the worst RFS and OS while patients with negativity for both
measures had the longest periods of RFS and OS among these patients.
Furthermore, patients either positive plasma EBV-DNA or serum VCA-
IgA had signiﬁcantly shorter survival periods than those with negativity
for bothmeasures. Furthermultivariate analyses revealed that positivity
for both plasma EBV-DNA and serum VCA-IgA was a risk factor for the
recurrence andmortality of NPC patients. Apparently, the risk for the re-
currence and mortality of NPC may range from patients with positivity
for both measures, positivity for either single measure to negativity for
both measures. Indeed, a recent study has shown that the contents of
plasma EBV-DNA, together with a new clinical typing system, can strat-
ify the NPC patients into four distinct risk groups and are valuable for
the prognosis of NPC [36]. Hence, simultaneous tests of plasma EBV-
DNA and serum VCA-IgA are valuable to identify the NPC patients at
high risk for the recurrence andmortality. Accordingly, we should close-
ly follow up those patientswith positivity for bothmeasures to early de-
tect and treat the recurrence and metastasis of NPC. To the best of our
knowledge, this was the ﬁrst study on the value of combination of
EBV-DNA and VCA-IgA in the prognosis of NPC patients. Our ﬁndings
may provide new references for clinical practice. We are interested in
further investigating the clinical signiﬁcance of early aggressive treat-
ment of patients with positivity for both measures.
Fig. 2. Stratiﬁcation analyses of the survival of NPC patients. All of theNPC patientswere stratiﬁed, according to the positivity for both EBV-DNAand VCA-IgA, for single positivemeasure or
negative for both measures, and their NPC relapse andmortality were calculated. Subsequently, the periods of RFS and OS of individual groups of patients were estimated by the Kaplan–
Meier method and analyzed by the Log rank test. (A) The percentages of relapse. (B) The percentages of RFS in the different groups of NPC patients throughout the observation period.
(C) The percentages of mortality. (D) The percentages of OS in the different groups of patients throughout the observation period.
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tive study with limited sample size, most patients with pathologic type
III of NPC and small sample size for the patients with positively serum
VCA-IgA alone. In this case, we had no strong data to distinguish the
risk between the patients with EBV-DNA alone and VCA-IgA alone.
Therefore, further prospective studies in a bigger population to validate
these ﬁndings and dissect the risk for the recurrence and mortality be-
tween patients with positivity for either EBV-DNA or VCA-IgA as well
as the levels of plasma EBV-DNA and serum VCA-IgA in the prognosis
of NPC are warranted.
5. Conclusions
In summary, our data indicated that positivity for both plasma EBV-
DNA and serum IgA had a signiﬁcantly higher risk for the recurrence
and mortality in patients with NPC. Simultaneous tests of both EBV-
DNA and VCA-IgAmay be valuable for the prognosis of NPC in the clinic.Table 3
Relapse-free and overall survival analyses using a multivariate Cox proportional hazards mode
Parameter R
H
Age: ≥44 y vs b44 y 1
Sex: men vs women 0
Tumor classiﬁcation:T1, T2, T3, and T4 1
Lymph node status: N0, N1, N2, and N3 1
Metastasis status: 1 vs 0 0
Markers: (DNA+, IgA+), (DNA+, IgA−) or (DNA−, IgA+), (DNA−, IgA−)*
(DNA+, IgA+) 3
(DNA+, IgA−) or (DNA−, IgA+) 2
Pa values were determined using the Wald test. *(DNA−, IgA−) was deﬁned as reference groTherefore, our ﬁndings may provide a new reference for management of
patients with NPC in the clinic.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2014.10.003.
Conﬂict of interest disclosures
The authors made no disclosures.
Acknowledgments
This studywas supported by grants from the National Science Foun-
dation of China-Guangdong Joint Fund (U1132003, to X.P.L.), the Natu-
ral Science Foundation of Guangdong Province (S2013010015685, to
X.L.) and the Foundation for Distinguished Young Talents in Higher Ed-
ucation of Guangdong (2012LYM0039, to J.L.).l.
FS OS
R (95% CI) Pa HR (95% CI) Pa
.195 (0.819, 1.743) 0.357 1.976 (1.268, 3.079) 0.003
.665 (0.411, 1.074) 0.095 0.893 (0.543, 1.469) 0.656
.152 (0.962, 1.379) 0.125 1.378 (1.118, 1.698) 0.003
.555 (1.248, 1.937) b0.001 1.639 (1.261, 2.131) b0.001
.323 (0.078, 1.332) 0.118 4.842 (2.721, 8.618) b0.001
0.001 0.002
.644 (1.717, 7.732) 0.001 3.972 (1.554, 10.153) 0.004
.400 (1.131, 5.096) 0.023 2.226 (0.863, 5.739) 0.098
up.
93F.-P. Zhao et al. / BBA Clinical 2 (2014) 88–93References
[1] W.I. Wei, J.S. Sham, Nasopharyngeal carcinoma, Lancet 365 (2005) 2041–2054.
[2] N. Lee, P. Xia, J.M. Quivey, K. Sultanem, I. Poon, C. Akazawa, P. Akazawa, V.Weinberg,
K.K. Fu, Intensity-modulated radiotherapy in the treatment of nasopharyngeal carci-
noma: an update of the UCSF experience, Int. J. Radiat. Oncol. Biol. Phys. 53 (2002)
12–22.
[3] J.C. Lin, J.S. Jan, C.Y. Hsu, W.M. Liang, R.S. Jiang,W.Y. Wang, Phase III study of concur-
rent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal
carcinoma: positive effect on overall and progression-free survival, J. Clin. Oncol.
21 (2003) 631–637.
[4] A.W. Lee, W.M. Sze, J.S. Au, S.F. Leung, T.W. Leung, D.T. Chua, B.C. Zee, S.C. Law, P.M.
Teo, S.Y. Tung, D.L. Kwong, W.H. Lau, Treatment results for nasopharyngeal carcino-
ma in the modern era: the Hong Kong experience, Int. J. Radiat. Oncol. Biol. Phys. 61
(2005) 1107–1116.
[5] Y.S. Chang, Y.S. Tyan, S.T. Liu, M.S. Tsai, C.C. Pao, Detection of Epstein–Barr virus DNA
sequences in nasopharyngeal carcinoma cells by enzymatic DNA ampliﬁcation, J.
Clin. Microbiol. 28 (1990) 2398–2402.
[6] R. Pathmanathan, U. Prasad, G. Chandrika, R. Sadler, K. Flynn, N. Raab-Traub, Undif-
ferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Var-
iants of Epstein–Barr virus-infected neoplasia, Am. J. Pathol. 146 (1995) 1355–1367.
[7] Y.M. Lo, L.Y. Chan, K.W. Lo, S.F. Leung, J. Zhang, A.T. Chan, J.C. Lee, N.M. Hjelm, P.J.
Johnson, D.P. Huang, Quantitative analysis of cell-free Epstein–Barr virus DNA in
plasma of patients with nasopharyngeal carcinoma, Cancer Res. 59 (1999)
1188–1191.
[8] Y.M. Lo, L.Y. Chan, A.T. Chan, S.F. Leung, K.W. Lo, J. Zhang, J.C. Lee, N.M. Hjelm, P.J.
Johnson, D.P. Huang, Quantitative and temporal correlation between circulating
cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcino-
ma, Cancer Res. 59 (1999) 5452–5455.
[9] K.C. Chan, E.C. Hung, J.K. Woo, P.K. Chan, S.F. Leung, F.P. Lai, A.S. Cheng, S.W. Yeung,
Y.W. Chan, T.K. Tsui, J.S. Kwok, A.D. King, A.T. Chan, A.C. van Hasselt, Y.M. Lo, Early
detection of nasopharyngeal carcinoma by plasma Epstein–Barr virus DNA analysis
in a surveillance program, Cancer 119 (2013) 1838–1844.
[10] A.T. Chan, Y.M. Lo, B. Zee, L.Y. Chan, B.B. Ma, S.F. Leung, F. Mo, M. Lai, S. Ho, D.P.
Huang, P.J. Johnson, Plasma Epstein–Barr virus DNA and residual disease after radio-
therapy for undifferentiated nasopharyngeal carcinoma, J. Natl. Cancer Inst. 94
(2002) 1614–1619.
[11] M. Adham, A.E. Greijer, S.A. Verkuijlen, H. Juwana, S. Fleig, L. Rachmadi, O. Malik,
A.N. Kurniawan, A. Roezin, S. Gondhowiardjo, D. Atmakusumah, S.J. Stevens, B.
Hermani, I.B. Tan, J.M. Middeldorp, Epstein–Barr virus DNA load in nasopharyngeal
brushings and whole blood in nasopharyngeal carcinoma patients before and after
treatment, Clin. Cancer Res. 19 (2013) 2175–2186.
[12] Y.M. Lo, A.T. Chan, L.Y. Chan, S.F. Leung, C.W. Lam, D.P. Huang, P.J. Johnson, Molecu-
lar prognostication of nasopharyngeal carcinoma by quantitative analysis of circu-
lating Epstein–Barr virus DNA, Cancer Res. 60 (2000) 6878–6881.
[13] J.C. Lin, W.Y. Wang, K.Y. Chen, Y.H. Wei, W.M. Liang, J.S. Jan, R.S. Jiang, Quantiﬁcation
of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carci-
noma, N. Engl. J. Med. 350 (2004) 2461–2470.
[14] W.Y. Wang, C.W. Twu, H.H. Chen, J.S. Jan, R.S. Jiang, J.Y. Chao, K.L. Liang, K.W. Chen,
C.T. Wu, J.C. Lin, Plasma EBV DNA clearance rate as a novel prognostic marker for
metastatic/recurrent nasopharyngeal carcinoma, Clin. Cancer Res. 16 (2010)
1016–1024.
[15] W.Y. Wang, C.W. Twu, H.H. Chen, R.S. Jiang, C.T. Wu, K.L. Liang, Y.T. Shih, C.C. Chen,
P.J. Lin, Y.C. Liu, J.C. Lin, Long-term survival analysis of nasopharyngeal carcinoma by
plasma Epstein–Barr virus DNA levels, Cancer 119 (2013) 963–970.
[16] H.B. Neel III, G.R. Pearson, W.F. Taylor, Antibody-dependent cellular cytotoxicity. Re-
lation to stage and disease course in North American patients with nasopharyngeal
carcinoma, Arch. Otolaryngol. 110 (1984) 742–747.
[17] F. de-Vathaire, H. Sancho-Garnier, H. de-The, C. Pieddeloup, G. Schwaab, J.H. Ho, R.
Ellouz, C. Micheau, M. Cammoun, Y. Cachin, et al., Prognostic value of EBV markers
in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter
follow-up study, Int. J. Cancer 42 (1988) 176–181.
[18] M.F. Ji, D.K. Wang, Y.L. Yu, Y.Q. Guo, J.S. Liang, W.M. Cheng, Y.S. Zong, K.H. Chan, S.P.
Ng,W.I. Wei, D.T. Chua, J.S. Sham, M.H. Ng, Sustained elevation of Epstein–Barr virus
antibody levels preceding clinical onset of nasopharyngeal carcinoma, Br. J. Cancer
96 (2007) 623–630.[19] W. Ling, S.M. Cao, Q.H. Huang, Y.H. Li, M.Q. Deng, Prognostic implication of pretreat-
ment titer of serum immunoglobulin A against Epstein–Barr virus capsid antigen in
nasopharyngeal carcinoma patients in Sihui, Guangdong, Ai Zheng 28 (2009) 57–59.
[20] N.M. Baizig, P. Morand, J.M. Seigneurin, H. Boussen, A. Fourati, S. Gritli, Z. Oueslati, S.
Touati, A. Gamoudi, M. Ben Abdallah, M. El May, A. El May, Complementary determi-
nation of Epstein–Barr virus DNA load and serum markers for nasopharyngeal car-
cinoma screening and early detection in individuals at risk in Tunisia, Eur. Arch.
Otorhinolaryngol. 269 (2012) 1005–1011.
[21] Y.L. Cai, J. Li, A.Y. Lu, W.M. Zhong, Y.M. Zheng, J.Q. Gao, H. Zeng, W.S. Chen, W. Liang,
M.Z. Tang, Prognostic signiﬁcance of serum anti-Epstein–Barr virus antibodies in na-
sopharyngeal carcinoma, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 27
(2013) 119–122.
[22] H. Fan, J. Nicholls, D. Chua, K.H. Chan, J. Sham, S. Lee, M.L. Gulley, Laboratory markers
of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and
serologic tests for Epstein–Barr virus, Int. J. Cancer 112 (2004) 1036–1041.
[23] K.C. Chan, A.T. Chan, S.F. Leung, J.C. Pang, A.Y. Wang, J.H. Tong, K.F. To, L.Y. Chan, L.L.
Tam, N.Y. Chung, J. Zhang, K.W. Lo, D.P. Huang, Y.M. Lo, Investigation into the origin
and tumoral mass correlation of plasma Epstein–Barr virus DNA in nasopharyngeal
carcinoma, Clin. Chem. 51 (2005) 2192–2195.
[24] Y.M. Lo, S.F. Leung, L.Y. Chan, A.T. Chan, K.W. Lo, P.J. Johnson, D.P. Huang, Kinetics of
plasma Epstein–Barr virus DNA during radiation therapy for nasopharyngeal carci-
noma, Cancer Res. 60 (2000) 2351–2355.
[25] E.W. To, K.C. Chan, S.F. Leung, L.Y. Chan, K.F. To, A.T. Chan, P.J. Johnson, Y.M. Lo, Rapid
clearance of plasma Epstein–Barr virus DNA after surgical treatment of nasopharyn-
geal carcinoma, Clin. Cancer Res. 9 (2003) 3254–3259.
[26] C.L. Hsu, K.P. Chang, C.Y. Lin, H.K. Chang, C.H.Wang, T.L. Lin, C.T. Liao, N.M. Tsang, L.Y.
Lee, S.C. Chan, S.H. Ng, H.P. Li, Y.S. Chang, H.M. Wang, Plasma Epstein–Barr virus
DNA concentration and clearance rate as novel prognostic factors for metastatic na-
sopharyngeal carcinoma, Head Neck 34 (2012) 1064–1070.
[27] S.F. Leung, A.T. Chan, B. Zee, B. Ma, L.Y. Chan, P.J. Johnson, Y.M. Lo, Pretherapy quan-
titative measurement of circulating Epstein–Barr virus DNA is predictive of
posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma
of undifferentiated type, Cancer 98 (2003) 288–291.
[28] D. Ferrari, C. Codeca, C. Bertuzzi, F. Broggio, F. Crepaldi, A. Luciani, I. Floriani, M.
Ansarin, F. Chiesa, D. Alterio, P. Foa, Role of plasma EBV DNA levels in predicting re-
currence of nasopharyngeal carcinoma in a Western population, BMC Cancer 12
(2012) 208.
[29] J.Y. Chan, S.T. Wong, The role of plasma Epstein–Barr virus DNA in the management
of recurrent nasopharyngeal carcinoma, Laryngoscope 124 (2014) 126–130.
[30] Y.C. Chien, J.Y. Chen, M.Y. Liu, H.I. Yang, M.M. Hsu, C.J. Chen, C.S. Yang, Serologic
markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in
Taiwanese men, N. Engl. J. Med. 345 (2001) 1877–1882.
[31] S.M. Cao, Z. Liu, W.H. Jia, Q.H. Huang, Q. Liu, X. Guo, T.B. Huang, W. Ye, M.H. Hong,
Fluctuations of Epstein–Barr virus serological antibodies and risk for nasopharyn-
geal carcinoma: a prospective screening study with a 20-year follow-up, PLoS One
6 (2011) e19100.
[32] J.Y. Shao, Y.H. Li, H.Y. Gao, Q.L.Wu, N.J. Cui, L. Zhang, G. Cheng, L.F. Hu, I. Ernberg, Y.X.
Zeng, Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV
immunoglobulin A/virus capsid antigen antibody titers in patients with nasopha-
ryngeal carcinoma, Cancer 100 (2004) 1162–1170.
[33] S.F. Leung, J.S. Tam, A.T. Chan, B. Zee, L.Y. Chan, D.P. Huang, A. Van Hasselt, P.J.
Johnson, Y.M. Lo, Improved accuracy of detection of nasopharyngeal carcinoma by
combined application of circulating Epstein–Barr virus DNA and anti-Epstein–Barr
viral capsid antigen IgA antibody, Clin. Chem. 50 (2004) 339–345.
[34] S. Kondo, T. Horikawa, H. Takeshita, C. Kanegane, Y. Kasahara, T.S. Sheen, H. Sato, M.
Furukawa, T. Yoshizaki, Diagnostic value of serum EBV-DNA quantiﬁcation and an-
tibody to viral capsid antigen in nasopharyngeal carcinoma patients, Cancer Sci. 95
(2004) 508–513.
[35] C.W. Twu,W.Y. Wang,W.M. Liang, J.S. Jan, R.S. Jiang, J. Chao, Y.T. Jin, J.C. Lin, Compar-
ison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA as-
says in nasopharyngeal carcinoma, Int. J. Radiat. Oncol. Biol. Phys. 67 (2007)
130–137.
[36] Peng Sun, Cui Chen, Xin-Lin Chen, Yi-Kan Cheng, Lei Zeng, Zhi-Jian Zeng, Li-Zhi Liu,
Su. Yong, Gu. Mo-Fa, Proposal of a clinical typing system and generation of a prog-
nostic model in patients with nasopharyngeal carcinoma from Southern China, J.
BUON 19 (2014) 474–483.
